Aurélien Marabelle

Aurélien Marabelle's indexed work centers on immune checkpoint blockade in mismatch repair–deficient and microsatellite instability–high cancers, where his first-author analyses of the KEYNOTE-158 cohorts helped establish tumour mutational burden as a predictive biomarker and supported pembrolizumab's tumour-agnostic approval. His senior-author position paper on managing immune-related dysimmune toxicities became a widely used reference for toxicity grading and treatment, and his reviews on intratumoural administration and tumour-tissue targeting of immunotherapies outline a parallel program of local delivery to convert the tumour itself into an immunization site. Earlier and collaborative contributions include characterizing hyperprogressive disease as a distinct pattern of progression on anti-PD-1/PD-L1 therapy and imaging-based assessment of tumour-infiltrating CD8 cells as a radiomic biomarker of response, alongside a middle-author role in a Cell study of calprotectin and myeloid subsets in severe COVID-19